Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10316/107532 https://doi.org/10.1038/s41419-017-0154-9 |
Resumo: | Protein kinase C (PKC) isozymes play major roles in human diseases, including cancer. Yet, the poor understanding of isozymes-specific functions and the limited availability of selective pharmacological modulators of PKC isozymes have limited the clinical translation of PKC-targeting agents. Here, we report the first small-molecule PKCδ-selective activator, the 7α-acetoxy-6β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), which binds to the PKCδ-C1-domain. Roy-Bz potently inhibited the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activation. In HCT116 colon cancer cells, Roy-Bz specifically triggered the translocation of PKCδ but not other phorbol ester responsive PKCs. Roy-Bz caused a marked inhibition in migration of HCT116 cells in a PKCδ-dependent manner. Additionally, the impairment of colonosphere growth and formation, associated with depletion of stemness markers, indicate that Roy-Bz also targets drug-resistant cancer stem cells, preventing tumor dissemination and recurrence. Notably, in xenograft mouse models, Roy-Bz showed a PKCδ-dependent antitumor effect, through anti-proliferative, pro-apoptotic, and anti-angiogenic activities. Besides, Roy-Bz was non-genotoxic, and in vivo it had no apparent toxic side effects. Collectively, our findings reveal a novel promising anticancer drug candidate. Most importantly, Roy-Bz opens the way to a new era on PKC biology and pharmacology, contributing to the potential redefinition of the structural requirements of isozyme-selective agents, and to the re-establishment of PKC isozymes as feasible therapeutic targets in human diseases. |
id |
RCAP_dda49f600c408516187619b70b6e9848 |
---|---|
oai_identifier_str |
oai:estudogeral.uc.pt:10316/107532 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapyColonic NeoplasmsHumansProtein Kinase C-deltaProtein kinase C (PKC) isozymes play major roles in human diseases, including cancer. Yet, the poor understanding of isozymes-specific functions and the limited availability of selective pharmacological modulators of PKC isozymes have limited the clinical translation of PKC-targeting agents. Here, we report the first small-molecule PKCδ-selective activator, the 7α-acetoxy-6β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), which binds to the PKCδ-C1-domain. Roy-Bz potently inhibited the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activation. In HCT116 colon cancer cells, Roy-Bz specifically triggered the translocation of PKCδ but not other phorbol ester responsive PKCs. Roy-Bz caused a marked inhibition in migration of HCT116 cells in a PKCδ-dependent manner. Additionally, the impairment of colonosphere growth and formation, associated with depletion of stemness markers, indicate that Roy-Bz also targets drug-resistant cancer stem cells, preventing tumor dissemination and recurrence. Notably, in xenograft mouse models, Roy-Bz showed a PKCδ-dependent antitumor effect, through anti-proliferative, pro-apoptotic, and anti-angiogenic activities. Besides, Roy-Bz was non-genotoxic, and in vivo it had no apparent toxic side effects. Collectively, our findings reveal a novel promising anticancer drug candidate. Most importantly, Roy-Bz opens the way to a new era on PKC biology and pharmacology, contributing to the potential redefinition of the structural requirements of isozyme-selective agents, and to the re-establishment of PKC isozymes as feasible therapeutic targets in human diseases.Springer Nature2018-01-18info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://hdl.handle.net/10316/107532http://hdl.handle.net/10316/107532https://doi.org/10.1038/s41419-017-0154-9eng2041-4889Bessa, CláudiaSoares, JoanaRaimundo, LilianaLoureiro, Joana B.Gomes, CéliaReis, FlávioSoares, Miguel L.Santos, DanielDureja, ChetnaChaudhuri, Saumya R.Lopez-Haber, CynthiaKazanietz, Marcelo G.Gonçalves, JorgeSimões, Maria F.Rijo, PatríciaSaraiva, Lucíliainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-19T08:40:32Zoai:estudogeral.uc.pt:10316/107532Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:23:52.698178Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
title |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
spellingShingle |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy Bessa, Cláudia Colonic Neoplasms Humans Protein Kinase C-delta |
title_short |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
title_full |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
title_fullStr |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
title_full_unstemmed |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
title_sort |
Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy |
author |
Bessa, Cláudia |
author_facet |
Bessa, Cláudia Soares, Joana Raimundo, Liliana Loureiro, Joana B. Gomes, Célia Reis, Flávio Soares, Miguel L. Santos, Daniel Dureja, Chetna Chaudhuri, Saumya R. Lopez-Haber, Cynthia Kazanietz, Marcelo G. Gonçalves, Jorge Simões, Maria F. Rijo, Patrícia Saraiva, Lucília |
author_role |
author |
author2 |
Soares, Joana Raimundo, Liliana Loureiro, Joana B. Gomes, Célia Reis, Flávio Soares, Miguel L. Santos, Daniel Dureja, Chetna Chaudhuri, Saumya R. Lopez-Haber, Cynthia Kazanietz, Marcelo G. Gonçalves, Jorge Simões, Maria F. Rijo, Patrícia Saraiva, Lucília |
author2_role |
author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Bessa, Cláudia Soares, Joana Raimundo, Liliana Loureiro, Joana B. Gomes, Célia Reis, Flávio Soares, Miguel L. Santos, Daniel Dureja, Chetna Chaudhuri, Saumya R. Lopez-Haber, Cynthia Kazanietz, Marcelo G. Gonçalves, Jorge Simões, Maria F. Rijo, Patrícia Saraiva, Lucília |
dc.subject.por.fl_str_mv |
Colonic Neoplasms Humans Protein Kinase C-delta |
topic |
Colonic Neoplasms Humans Protein Kinase C-delta |
description |
Protein kinase C (PKC) isozymes play major roles in human diseases, including cancer. Yet, the poor understanding of isozymes-specific functions and the limited availability of selective pharmacological modulators of PKC isozymes have limited the clinical translation of PKC-targeting agents. Here, we report the first small-molecule PKCδ-selective activator, the 7α-acetoxy-6β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), which binds to the PKCδ-C1-domain. Roy-Bz potently inhibited the proliferation of colon cancer cells by inducing a PKCδ-dependent mitochondrial apoptotic pathway involving caspase-3 activation. In HCT116 colon cancer cells, Roy-Bz specifically triggered the translocation of PKCδ but not other phorbol ester responsive PKCs. Roy-Bz caused a marked inhibition in migration of HCT116 cells in a PKCδ-dependent manner. Additionally, the impairment of colonosphere growth and formation, associated with depletion of stemness markers, indicate that Roy-Bz also targets drug-resistant cancer stem cells, preventing tumor dissemination and recurrence. Notably, in xenograft mouse models, Roy-Bz showed a PKCδ-dependent antitumor effect, through anti-proliferative, pro-apoptotic, and anti-angiogenic activities. Besides, Roy-Bz was non-genotoxic, and in vivo it had no apparent toxic side effects. Collectively, our findings reveal a novel promising anticancer drug candidate. Most importantly, Roy-Bz opens the way to a new era on PKC biology and pharmacology, contributing to the potential redefinition of the structural requirements of isozyme-selective agents, and to the re-establishment of PKC isozymes as feasible therapeutic targets in human diseases. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-01-18 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10316/107532 http://hdl.handle.net/10316/107532 https://doi.org/10.1038/s41419-017-0154-9 |
url |
http://hdl.handle.net/10316/107532 https://doi.org/10.1038/s41419-017-0154-9 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2041-4889 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Springer Nature |
publisher.none.fl_str_mv |
Springer Nature |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134125080182784 |